Incyte Streamlines Pipeline After Difficult Q1
Company Still Looking For Jakafi Combination
The mid-sized pharma company has a blockbuster in Jakafi, but analysts are doubtful about its plans to build on that base across its now slimmed-down pipeline.
You may also be interested in...
Incyte’s topical JAK inhibitor carries a class-wide severe safety warning and cautions against chronic use, but 52-week results could ease the way for the potential vitiligo indication.
After discussions with the FDA, which has made its feelings clear on accelerated approvals, Incyte has concluded it cannot complete the confirmatory trials in lymphomas that would be needed on parsaclisib in time to make them worth their while.
The withdrawal of the targeted anticancer comes as no surprise after its Phase III missed in July, but it sets back Takeda’s expansion plans in the competitive therapy area.